CANF News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CA

Mkt Cap

$3.8M

Volume

26.97K

Loading chart

CA

CANFCan-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares

CANF

Pay with—

Available Balance0.00

CA

Mkt Cap

$4.0M

Volume

26.97K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in OncologyCan-Fite BioPharma announced that its Phase 2a study results for Namodenoson in advanced pancreatic cancer patients have been accepted for poster presentation at ESMO Congress 2026. The study demonstrated durable disease stabilization and encouraging survival outcomes in third-line pancreatic cancer patients, with one patient remaining alive over 18 months after second-line treatment. The company plans to advance to a Phase 2b study combining Namodenoson with chemotherapy.GlobeNewswire Inc. · Jul 20, 2026

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightOver 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.GlobeNewswire Inc. · Apr 14, 2026

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer StudyCan-Fite BioPharma announced positive Phase IIa results for namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC), meeting its primary safety endpoint with no new safety signals identified. The study enrolled 20 heavily pretreated patients, with 1/3 currently alive at data cutoff. Survival outcomes remain under follow-up and will be reported at upcoming scientific meetings.GlobeNewswire Inc. · Mar 4, 2026

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio ChangeCan-Fite BioPharma announced a 1-for-3,000 reverse stock split of its ordinary shares, approved by shareholders on November 10, 2025, effective January 5, 2026 on the Tel-Aviv Stock Exchange and NYSE American. The reverse split will also adjust the ADS ratio from 1 ADS representing 300 ordinary shares to 1 ADS representing 2 ordinary shares, equivalent to a 1-for-20 ADS split. The company's authorized shares will be reduced from 42 billion to 14 million.GlobeNewswire Inc. · Dec 23, 2025

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological BenefitsCan-Fite BioPharma's drug Namodenoson has shown promising results in treating liver cancer, as well as providing protective effects on the heart, liver, and nervous system, unlike traditional chemotherapy. The study highlights Namodenoson's ability to increase adiponectin levels, a key cytokine known to drive multi-organ protective effects.GlobeNewswire Inc. · Mar 3, 2025

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025Can-Fite BioPharma, a biotechnology company, announced that it will present its lead drug candidate Namodenoson, which is in late-stage trials for liver cancer and metabolic disorders, at the upcoming BIO CEO & Investor Conference.GlobeNewswire Inc. · Feb 5, 2025

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialCan-Fite BioPharma has dosed the first patient in a Phase IIa clinical trial evaluating its drug Namodenoson in patients with advanced pancreatic adenocarcinoma. The trial aims to assess the safety, clinical activity, and pharmacokinetics of Namodenoson in this patient population.GlobeNewswire Inc. · Nov 11, 2024

Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral TherapiesThe article discusses the growing demand for convenient, less invasive treatment options for psoriasis, with oral therapies gaining traction and potentially challenging the dominance of injectable biologics. Several promising oral pipeline agents, including from Johnson & Johnson, Alumis, Takeda, and Bristol Myers Squibb, are highlighted as potential disruptors in the market.GlobeNewswire Inc. · Oct 16, 2024

Hepatic Tumor Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the DomainThe hepatic tumor market is driven by the increasing incidence of liver cancer, advancements in treatment options, and the growing emphasis on personalized medicine and combination therapies. The pipeline comprises 75+ companies working on 75+ pipeline therapies, with several promising candidates in different phases of clinical trials.GlobeNewswire Inc. · Jul 30, 2024

Can-Fite (CANF) Up on Liver Cancer Study Update of NamodenosonCan-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.Zacks Investment Research · Nov 22, 2023

to start trading

CA

CANFCan-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares

CANF

Pay with—

Available Balance0.00

Your PositionYou don't own any CANF yet.

Related Tickers

Earnings